N-[(1-piperidinyl)alkyl]arylcarboxamide derivatives

Claim 1

A chemical compound selected from the group consisting of a N-[(1-piperidinyl)alkyl]arylcarboxamide derivative having the formula: ##STR80## and the pharmaceutically acceptable acid addition salts thereof, wherein: Ar is an aryl radical selected from the group consisting of phenyl, substituted phenyl, 2-thienyl, 2-furanyl, pyridinyl and 1-methyl-2-pyrrolyl, wherein said substituted phenyl is phenyl having from 1 to 3 substituents independently selected from the group consisting of halo, lower alkyl, lower alkyloxy, trifluoromethyl, nitro, hydroxy, amino, lower alkylcarbonyloxy and lower alkylcarbonylamino, provided that when more than 1 of said substituents are present only one thereof may be selected from the group consisting of hydroxy, amino, lower alkylcarbonyloxy and lower alkylcarbonylamino; R is a member selected from the group consisting of hydrogen and lower alkyl; n is an integer of from 2 to 3 inclusive; and ##STR81## is a member selected from the group consisting of a. a radical having the formula: ##STR82## wherein R 1 and R 2 are each independently selected from the group consisting of hydrogen, halo, lower alkyl and trifluoromethyl; b. a radical having the formula: ##STR83## wherein R 3 and R 4 are each independently selected from the group consisting of hydrogen, halo, lower alkyl and trifluoromethyl; M is selected from the group consisting of hydrogen, lower alkyl, lower alkylcarbonyl and 2-cyanoethyl; Y is selected from the group consisting of O, S and lower alkylcarbonylimino; and the dotted line indicates that the double bond between the 3- and 4-carbon atoms of the piperidine nucleus is optional, provided that when there is a double bond between said 3- and 4-carbon atoms, then said Y is O and said M is hydrogen; c. a radical having the formula: ##STR84## wherein R 3 and R 4 are each independently selected from the group consisting of hydrogen, halo, lower alkyl and trifluoromethyl; and d. a radical having the formula: ##STR85## wherein R 5 is selected from the group consisting of hydrogen and methyl; R 6 is selected from the group consisting of hydrogen and halo; and R 7 is selected from the group consisting of hydrogen, halo, lower alkyl and trifluoromethyl.

Claim 26

A method of inhibiting emesis or mental disorders which comprises the systemic administration to warm-blooded animals of an effective antimetic or psychotropic amount of a compound selected from the group consisting of a N-[(1-piperidinyl)alkyl]arylcarboxamide derivative having the formula: ##STR98## and the pharmaceutically acceptable acid addition salts thereof, wherein: Ar is an aryl radical selected from the group consisting of phenyl, substituted phenyl, 2-thienyl, 2-furanyl, pyridinyl and 1-methyl-2-pyrrolyl, wherein said substituted phenyl is phenyl having from 1 to 3 substituents independently selected from the group consisting of halo, lower alkyl, lower alkyloxy, trifluoromethyl, nitro, hydroxy, amino, lower alkylcarbonyloxy and lower alkylcarbonylamino, provided that when more than 1 of said substituents are present only one thereof may be selected from the group consisting of hydroxy, amino, lower alkylcarbonyloxy and lower alkylcarbonylamino; R is a member selected from the group consisting of hydrogen and lower alkyl; n is an integer of from 2 to 3 inclusive; and the radical ##STR99## is a member selected from the group consisting of a. a radical having the formula: ##STR100## wherein R 1 and R 2 are each independently selected from the group consisting of hydrogen, halo, lower alkyl and trifluoromethyl; b. a radical having the formula: ##STR101## wherein R 3 and R 4 are each independently selected from the group consisting of hydrogen, halo, lower alkyl and trifluoromethyl; M is selected from the group consisting of hydrogen, lower alkyl, lower alkylcarbonyl and 2-cyanoethyl; Y is selected from the group consisting of O, S and lower alkylcarbonylimino; and the dotted line indicates that the double bond between the 3- and 4-carbon atoms of the piperidine nucleus is optional, provided that when there is a double bond between said 3- and 4-carbon atoms, then said Y is O and said M is hydrogen; c. a radical having the formula: ##STR102## wherein R 3 and R 4 are each independently selected from the group consisting of hydrogen, halo, lower alkyl and trifluoromethyl; and d. a radical having the formula: ##STR103## wherein R 5 is selected from the group consisting of hydrogen and methyl; R 6 is selected from the group consisting of hydrogen and halo; and R 7 is selected from the group consisting of hydrogen, halo, lower alkyl and trifluoromethyl; in admixture with a pharmaceutical carrier.

Claim 27

A method of inhibiting emesis or mental disorders which comprises the systemic administration to warm-blooded animals of an effective antimetic or psychotropic amount of a compound selected from the group consisting of a N-[(1-piperidinyl)alkyl]arylcarboxamide derivative having the formula: ##STR98## and the pharmaceutically acceptable acid addition salts thereof, wherein: Ar is an aryl radical selected from the group consisting of phenyl, substituted phenyl, 2-thienyl, 2-furanyl, pyridinyl and 1-methyl-2-pyrrolyl, wherein said substituted phenyl is phenyl having from 1 to 3 substituents independently selected from the group consisting of halo, lower alkyl, lower alkyloxy, trifluoromethyl, nitro, hydroxy, amino, lower alkylcarbonyloxy and lower alkylcarbonylamino, provided that when more than 1 of said substituents are present only one thereof may be selected from the group consisting of hydroxy, amino, lower alkylcarbonyloxy and lower alkylcarbonylamino; R is a member selected from the group consisting of hydrogen and lower alkyl; n is an integer of from 2 to 3 inclusive; and the radical ##STR99## is a member selected from the group consisting of a. a radical having the formula: ##STR100## wherein R 1 and R 2 are each independently selected from the group consisting of hydrogen, halo, lower alkyl and trifluoromethyl; b. a radical having the formula: ##STR101## wherein R 3 and R 4 are each independently selected from the group consisting of hydrogen, halo, lower alkyl and trifluoromethyl; M is selected from the group consisting of hydrogen, lower alkyl, lower alkylcarbonyl and 2-cyanoethyl; Y is selected from the group consisting of O, S and lower alkylcarbonylimino; and the dotted line indicates that the double bond between the 3- and 4-carbon atoms of the piperidine nucleus is optional, provided that when there is a double bond between said 3- and 4-carbon atoms, then said Y is O and said M is hydrogen; c. a radical having the formula: ##STR102## wherein R 3 and R 4 are each independently selected from the group consisting of hydrogen, halo, lower alkyl and trifluoromethyl; and d. a radical having the formula: ##STR103## wherein R 5 is selected from the group consisting of hydrogen and methyl; R 6 is selected from the group consisting of hydrogen and halo; and R 7 is selected from the group consisting of hydrogen, halo, lower alkyl and trifluoromethyl; in admixture with a pharmaceutical carrier.

Claim 28

A method of inhibiting emesis or mental disorders which comprises the systemic administration to warm-blooded animals of an effective antiemetic or psychotropic amount of N-{2-[4-(5-chloro-2,3-dihydro-2-oxo-1H-benzimidazol-1-yl)-1-piperidinyl]ethyl}-4-fluorobenzamide and the pharmaceutically acceptable acid addition salts thereof, in admixture with a pharmaceutical carrier.

Claim 29

A method of inhibiting emesis or mental disorders which comprises the systemic administration to warm-blooded animals of an effective antiemetic or psychotropic amount of N-{2-[4-(5-chloro-2,3-dihydro-2-oxo-1H-benzimidazol-1-yl)-1-piperidinyl]ethyl}-4-fluorobenzamide and the pharmaceutically acceptable acid addition salts thereof, in admixture with a pharmaceutical carrier.